- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02419183
A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment
June 30, 2016 updated by: Janssen Research & Development, LLC
A Randomized Cross-over, Controlled Feasibility, and Validation Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Subjects With Mild Cognitive Impairment
The purpose of this study is to evaluate the psychometric properties of a Self-administered Memory Screening Test with Automated Reporting (SAMSTAR) adapted from the Rey Auditory Verbal Learning Test (RAVLT) in normal control (NC) participants and participants with Mild Cognitive Impairment (MCI) against a standard version of the RAVLT test, administered by an examiner under the same conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a single-center (when only one hospital or medical school team work on a medical research study), randomized (participants are assigned to treatment by a chance), crossover (participants may receive different treatments sequentially during the trial) study.
The study consists of a Screening Phase (Day -3 up to and including Day 1), Test Phase (Test Day 1 and Test Day 2 [within 7 to 14 days following Test Day 1]) and an optional follow-up visit within 7 days after the last study-related activity for participants who experienced an adverse event that had not resolved by the end of the last test visit.The NC and MCI participants will initially either undergo a standard version of the RAVLT test or the SAMSTAR version of the RAVLT test on Test Day 1 or on the same day as screening, with follow-up testing using the other test using a crossover design to be conducted within 1 to 2 weeks at the same venue (Test Day 2).
There will be a 7-to 14-day memory washout period between the test periods.
No investigational medicinal product will be administered.
The maximum study duration for a participant will not exceed 3 weeks.
Study Type
Observational
Enrollment (Actual)
153
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
Durham, North Carolina, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
51 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Male and female adult normal control (NC) participants and participants with Mild Cognitive Impairment (MCI), aged 55 to 84 years receiving healthcare in primary care and/or neurology practice settings.
Description
Inclusion Criteria:
- Participant must have normal visual and hearing acuity (corrected or uncorrected) as assessed in the Screening cognitive test (MoCA)
Screening Criteria:
- NC participants: meet inclusion/exclusion criteria, Dementia Screening Interview (8- item) (AD8) score 0-1, MoCA score 28 or higher (education-adjusted)
- MCI participants: meet inclusion/exclusion criteria, AD8 score 2 or higher, MoCA score 24 to 27 (education-adjusted)
- Participant must be English-speaking and able to understand and follow the examiner/trial instructions
- Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study
Exclusion Criteria:
- Participant has an acute or chronic medical condition (eg, Alzheimer's disease [AD] or depression) that would interfere with the participant's ability to complete either memory test assessment or comply with other study requirements
- Participant has an acute or chronic psychiatric condition that would interfere with the participant's ability to complete either memory test assessment or comply with other study requirements
- Participant has any acute or chronic neurological conditions (eg, stroke, epilepsy, Parkinson's disease)
- Participant has any sensory, motor or speech impairment that would interfere with the participants' ability to complete memory testing that relies on speech recognition
- Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Sequence A
Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
|
This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
|
|
Sequence B
Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
|
This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Evaluation by Self-administered memory screening test with automated reporting (SAMSTAR)
Time Frame: Up to 3 weeks
|
The memory test will include a list of 15 words presented one at a time through the iPad (on screen and aloud).
After the 15-word list is presented, the participant will be asked to verbally recall as many of the words as possible.
|
Up to 3 weeks
|
|
Cognitive Evaluation by Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: Up to 3 weeks
|
The memory test will include a list of 15 words presented one at a time verbally by the examiner.
After the 15-word list is presented, the participant will be asked to verbally recall as many of the words as possible.
|
Up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the feasibility of SAMSTAR
Time Frame: Up to 3 weeks
|
The feasibility of using a SAMSTAR approach to cognitive screening will be evaluated by meeting target enrollment criteria and by survey data from participants and clinical staff about their experience and attitudes regarding cognitive screening as executed in this study.
|
Up to 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
April 14, 2015
First Submitted That Met QC Criteria
April 16, 2015
First Posted (Estimate)
April 17, 2015
Study Record Updates
Last Update Posted (Estimate)
July 1, 2016
Last Update Submitted That Met QC Criteria
June 30, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR106702
- NOPRODALZ0001 (Other Identifier: Janssen Research & Development, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Singapore General HospitalSingapore Health ServicesNot yet recruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment
-
Xuanwu Hospital, BeijingNot yet recruitingMild Cognitive Impairment (MCI)China
-
The Hong Kong Polytechnic UniversityJohns Hopkins University; The University of Hong Kong; University of ReadingNot yet recruitingMild Cognitive Impairment (MCI)Hong Kong
-
Universidad Complutense de MadridAB Biotics, SANot yet recruitingMild Cognitive Impairment (MCI)Spain
-
University of SheffieldNot yet recruitingMild Cognitive Impairment (MCI)United Kingdom
-
The Hong Kong Polytechnic UniversityRecruitingMild Cognitive Impairment (MCI)Hong Kong
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.TerminatedMild Cognitive Impairment (MCI)Taiwan